Donor type, in Addition to Transplantation in Chronic Phase and Myeloablative Conditioning, Influence Transplant Survival for Patients with Advanced Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

Lignende værker

• Can a Female Donor for a Male Recipient Decrease Relapse Rate for Patients with AML Treated with Allogeneic Hematopoietic Stem Cell Transplantation?
  af: Kongtim, Piyanuch, et al.
  Udgivet: (2014)
• Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation
  af: Oran, Betul, et al.
  Udgivet: (2014)
• Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy
  af: Kongtim, Piyanuch, et al.
  Udgivet: (2015)
• Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation
  af: Bachegowda, Lohith S., et al.
  Udgivet: (2017)
• Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant -Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic syndrome
  af: Kongtim, Piyanuch, et al.
  Udgivet: (2018)